Okay, I understand.Here’s the prompt you can use, wiht the placeholders as requested:
You are an expert news writer for Clinical Trials Arena, a leading source of news and analysis in the pharmaceutical and clinical trials industry.You are writing a news article based on the provided HTML content.Article Title: Tyra Biosciences Doses First Pediatric Patient in Dabogratinib Achondroplasia Trial
Article Summary: Tyra Biosciences has dosed the first pediatric patient in its Phase II BEACH301 trial of dabogratinib for children with achondroplasia. The trial will assess the efficacy and safety of the oral FGFR3-selective inhibitor.
Key Points to Include: The Phase II BEACH301 trial is a dose-escalation/dose-expansion trial.
The trial is open-label and multi-center.
Participants are children aged 3-10 years with achondroplasia and open growth plates.
The trial includes two cohorts: treatment-naïve and those previously treated with growth-accelerating therapy. Dose levels being tested: 0.125mg/kg,0.25mg/kg, 0.375mg/kg,and 0.50mg/kg.
A safety sentinel cohort will focus on children aged 5-10 years.
Primary goals: evaluate tolerability and safety, and measure change in annualized growth velocity.
Secondary objectives: assess changes in height z-score, pharmacokinetics, and proportionality.
Dabogratinib is a once-a-day, selective FGFR3 inhibitor developed using Tyra's SNÅP platform.
Quote from Tyra biosciences CEO Todd Harris: "Achondroplasia is caused by an alteration in FGFR3, and we believe that precisely targeting the root cause of this condition is the key to transforming care. Dabogratinib is the only oral, FGFR3-selective inhibitor in clinical growth for achondroplasia, reflecting our commitment to bring forward therapies that are both innovative and accessible for children and their families."
* Mention the Clinical Trials Arena Excellence Awards and encourage nominations.
Instructions:
Write a concise and informative news article based on the provided HTML.
Maintain a professional and objective tone.
Focus on the key facts and details of the trial and the drug.
Include the quote from the CEO to add impact.
Briefly mention the Clinical Trials arena Excellence Awards at the end of the article to drive engagement.
Do not include any personal opinions or interpretations.
Adhere to journalistic standards of accuracy and clarity.
The article should be approximately 300-400 words.
Provided HTML Content:
Achondroplasia is the most prevalent form of dwarfism. Credit: nik93737 / Shutterstock.com.
US-based Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial designed to assess the efficacy and safety of dabogratinib (TYRA-300), a treatment for children with achondroplasia, which is the most prevalent form of dwarfism.
The open-label, multi-centre trial targets children aged between three and ten years who have achondroplasia with open growth plates.
combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
It is set to include two cohorts of children: those who have not previously undergone treatment in Cohort 1 and those who have been subjected to growth-accelerating therapy in Cohort 2.
It is anticipated that up to ten subjects will be enrolled per dose level in each cohort, with the study lasting up to 12 months.
The dose levels being tested are 0.125mg/kg, 0.25mg/kg, 0.375mg/kg, and 0.50mg/kg.
Additionally, a safety sentinel cohort will be established, consisting of up to three subjects/dose level, focusing on those who are aged five to ten years.
The primary goals of the BEACH301 trial will evaluate the tolerability and safety of the oral therapy in the paediatric population with this condition and measure the change in annualised growth velocity from baseline.
This will aid in determining the appropriate dose(s) for subsequent phases of development.
Secondary objectives of the trial include the assessment of changes from baseline in height z-score, pharmacokinetics and proportionality.
Developed using the company's SNÅP platform, dabogratinib is a once-a-day medication that acts as a selective inhibitor of the fibroblast growth factor receptor 3 (FGFR3).
Tyra Biosciences CEO Todd Harris said: "Achondroplasia is caused by an alteration in FGFR3, and we believe that precisely targeting the root cause of this condition is the key to transforming care.
"Dabogratinib is the only oral, FGFR3-selective inhibitor in clinical development for achondroplasia, reflecting our commitment to bring forward therapies that are both innovative and accessible for children and their families."
heading wp-noreslt">Sign up for our daily news round-up!
sub-heading">Give your business an edge with our leading industry insights.
Clinical Trials Arena Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don't miss your chance to stand out-submit your entry today!
Nominate Now
Response (News Article):
Tyra Biosciences has announced the dosing of the first pediatric participant in the Phase II BEACH301 trial, evaluating dabogratinib (TYRA-300) for children with achondroplasia, the most common form of dwarfism. The open-label, multi-center trial is designed to assess the efficacy and safety of the oral drug in children aged three to ten years with achondroplasia and open growth plates.
The BEACH301 trial includes two cohorts: children who have not previously undergone treatment (Cohort 1) and those who have been subjected to growth-accelerating therapy (Cohort 2).Up to ten subjects will be enrolled per dose level in each cohort, with the study expected to last up to 12 months. The trial will test dose levels of 0.125mg/kg, 0.25mg/kg, 0.375mg/kg, and 0.50mg/kg. A safety sentinel cohort, consisting of up to three subjects per dose level aged five to ten years, will also be established.
The primary goals of the BEACH301 trial are to evaluate the tolerability and safety of dabogratinib in the pediatric population and to measure the change in annualized growth velocity from baseline. Secondary objectives include assessing changes from baseline in height z-score, pharmacokinetics, and proportionality.
Dabogratinib,developed using Tyra Biosciences' SNÅP platform,is a once-a-day medication that acts as a selective inhibitor of the fibroblast growth factor receptor 3 (FGFR3).
"Achondroplasia is caused by an alteration in FGFR3, and we believe that precisely targeting the root cause of this condition is the key to transforming care," said Tyra Biosciences CEO Todd harris. "Dabogratinib is the only oral, FGFR3-selective inhibitor in clinical development for achondroplasia, reflecting our commitment to bring forward therapies that are both innovative and accessible for children and their families."
Don't miss the chance to gain recognition for your achievements! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact in the clinical trials industry. Nominate your company today!
Clarification of How to Use this:
Copy the entire response (the news article text) into your CMS.
Publish the article.
This will give you a well-written news article based on the provided HTML, ready for publication on Clinical Trials Arena.
The Archynetys Health Desk covers public health, medical research, healthcare systems, wellness trends, and science-backed developments that affect readers globally. This desk applies added care to sourcing, evidence, nuance, and plain-language explanation, especially on high-impact health topics.
